Company Profile
Corporate Presentation

Recent Press Releases
Featured Event

Contact Us
Corporate Headquarters
VBI Vaccines Inc.
222 Third Street, Suite 2241
Cambridge, MA 02142
Telephone: (617) 830-3031
Email: ir@vbivaccines.com
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.
VBI Vaccines Inc.
222 Third Street, Suite 2241
Cambridge, MA 02142
Telephone: (617) 830-3031
Email: ir@vbivaccines.com
© 2020 VBI Vaccines Inc. | Disclaimer and Terms of Use